Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 276

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 276
---
 and diluted net loss per share attributable to common stockholders is the same. For the years ended December 31, 2024 and 2023, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period because including them would have had an anti-dilutive effect: 

        As of December 31,

        2024

        2023

        Preferred Series A (as converted)

        -

        7,053,338

        Preferred Series A-1 (as converted)

        -

        4,500,142

        Preferred Series B (as converted)

        -

        5,359,363

        Convertible Notes (as converted)

        -

        847,670

        Stock options issued and outstanding

        6,403,818

        2,781,064

        Unvested restricted stock units

        114

        -

        Warrants

        10,609,855

        8,083,775

        Total

        17,013,787

        28,625,352

Note 5—Fair value measurementsThe following tables present information about financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: 

        December 31, 2023

        Level 1

        Level 2

        Level 3

        Total

        Derivative Liability
         
        $
        -

        $
        -

        $
        137,000

        $
        137,000

        Total Liabilities
         
        $
        -

        $
        -

        $
        137,000

        $
        137,000

       There were no transfers between the Level 1, Level 2 or Level 3 categories during the years ended December 31, 2024 and 2023.

F-16

TUHURA BIOSCIENSES, INC AND SUBSIDIARIESNotes to the consolidated financial statementsFor the years ended December 31, 2024, and 2023  

Derivative LiabilityThe following table presents activity for the Derivative Liability that were measured at fair value using significant unobservable Level 3 inputs during the years ended December 31, 2024 and, 2023: 

        DerivativeLiability

         Balance as of January 1, 2023